As of close of business last night, Transmedics Group Inc’s stock clocked out at $75.35, up 3.76% from its previous closing price of $72.62. In other words, the price has increased by $+2.73 from its previous closing price. On the day, 1129173 shares were traded.
Ratios:
To gain a deeper understanding of TMDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.49 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 3.76 whereas as Long-Term Debt/Eq ratio is at 3.75.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on March 28, 2024, initiated with a Overweight rating and assigned the stock a target price of $95.
JP Morgan Upgraded its Neutral to Overweight on August 02, 2022, while the target price for the stock was maintained at $48.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Gordon Stephen sold 15,000 shares for $74.01 per share. The transaction valued at 1,110,150 led to the insider holds 23,299 shares of the business.
Gordon Stephen sold 1,903 shares of TMDX for $166,760 on Mar 08 ’24. The Chief Financial Officer now owns 23,299 shares after completing the transaction at $87.63 per share. On Mar 08 ’24, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 1,417 shares for $87.80 each. As a result, the insider received 124,413 and left with 25,185 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 2.37B and an Enterprise Value of 2.49B. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.20 while its Price-to-Book (P/B) ratio in mrq is 17.94. Its current Enterprise Value per Revenue stands at 10.33 whereas that against EBITDA is -323.89.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $99.63, while it has fallen to a 52-week low of $36.42. The 50-Day Moving Average of the stock is 82.44, while the 200-Day Moving Average is calculated to be 71.88.
Shares Statistics:
It appears that TMDX traded 636.92K shares on average per day over the past three months and 752.21k shares per day over the past ten days. A total of 32.67M shares are outstanding, with a floating share count of 31.48M. Insiders hold about 3.79% of the company’s shares, while institutions hold 109.01% stake in the company. Shares short for TMDX as of Mar 15, 2024 were 5.41M with a Short Ratio of 8.49, compared to 4.93M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 16.53% and a Short% of Float of 19.12%.
Earnings Estimates
As of right now, 5 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of $0.11 and a low estimate of -$0.33, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.04, with high estimates of $0.28 and low estimates of -$0.37.
Analysts are recommending an EPS of between $0.56 and -$1.24 for the fiscal current year, implying an average EPS of -$0.23. EPS for the following year is $0.32, with 5 analysts recommending between $1.55 and -$0.9.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $83.78M. It ranges from a high estimate of $85.5M to a low estimate of $81.2M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $41.55M, an estimated increase of 101.60% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $372.4M, while the lowest revenue estimate was $360M, resulting in an average revenue estimate of $366.99M. In the same quarter a year ago, actual revenue was $241.62M, up 51.90% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $489.97M in the next fiscal year. The high estimate is $539.8M and the low estimate is $450.14M. The average revenue growth estimate for next year is up 33.50% from the average revenue estimate for this year.
